Skip to main content
About Us
Image Credits
Contributor Info
RSS
Log In
Join
Twitter
E-Alerts
Visit StemJournal
Main menu
About
Image Credits
Contributor Info
E-Alerts
Chapters
Cellular and nuclear reprogramming
Ectoderm specification and differentiation
Endoderm specification and differentiation
Epigenetics
Genomics and proteomics
Germ cell and somatic stem cell biology in reproduction
Manufacturing
Mesoderm specification and differentiation
Niche biology, homing, and migration
Renewal
Stem cell immunology
Therapeutic prospects
Tissue engineering
Protocols
Ectoderm differentiation
Endoderm differentiation
Genome editing
Mesoderm differentiation
Pluripotent stem cells
PSC characterization
PSC genetic stability
Reprogramming
StemLabs
Stem Cell COREdinates
Core Facility Profiles
Boston Children's Hospital Human Neuron Core
Boston University Center for Regenerative Medicine iPSC Core
Columbia Stem Cell Initiative Stem Cell Core Facility
Harvard Stem Cell Institute iPS Core Facility
Stem Cell Protocols
Stem Cell Reagents
Other Resources
News & Profiles
Latest News
Stem Cell Institute Profiles
Journal Stream
Forum
Search form
Search
You are here
Home
Biblio
Author
[
Title
]
Type
Year
Filters:
Author
is
Huang, Xuelin
[Clear All Filters]
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
P
Jabbour E
,
Short NJ
,
Jain N
,
Huang X
,
Montalban-Bravo G
,
Banerjee P
,
Rezvani K
,
Jiang X
,
Kim KHee
,
Kanagal-Shamanna R
, et al.
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.
Lancet Haematol. 2022.
PubMed
Google Scholar
Short NJ
,
Jabbour EJ
,
Jain N
,
Senapati J
,
Nasr LFady
,
Haddad FG
,
Li Z
,
Hsiao Y-C
,
Yang JJ
,
Pemmaraju N
, et al.
A Phase 1/2 Study of Mini-Hyper-CVD plus Venetoclax in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.
Blood Adv. 2024.
PubMed
Google Scholar
Borthakur G
,
Zeng Z
,
Cortes JE
,
Chen H-C
,
Huang X
,
Konopleva M
,
Ravandi F
,
Kadia T
,
Patel KP
,
Daver N
, et al.
Phase 1 Study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients.
Am J Hematol. 2020.
PubMed
Google Scholar
O
Bataller A
,
Montalban-Bravo G
,
Bazinet A
,
Alvarado Y
,
Chien K
,
Venugopal S
,
Ishizawa J
,
Hammond D
,
Swaminathan M
,
Sasaki K
, et al.
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study.
Lancet Haematol. 2024.
PubMed
Google Scholar
M
Ravandi F
,
Jorgensen JL
,
O'Brien SM
,
Jabbour E
,
Thomas DA
,
Borthakur G
,
Garris R
,
Huang X
,
Garcia-Manero G
,
Burger JA
, et al.
Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia.
Br J Haematol. 2015.
PubMed
Google Scholar
L
Kadia TM
,
Ravandi F
,
Borthakur G
,
Konopleva M
,
Dinardo CD
,
Daver N
,
Pemmaraju N
,
Kanagal-Shamanna R
,
Wang X
,
Huang X
, et al.
Long-term Results of Low-intensity Chemotherapy with Clofarabine or Cladribine Combined with Low-Dose Cytarabine Alternating with Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia.
Am J Hematol. 2021.
PubMed
Google Scholar
H
Jabbour E
,
Richard-Carpentier G
,
Sasaki Y
,
Konopleva M
,
Patel K
,
Roberts K
,
Gu Z
,
Wang F
,
Huang X
,
Sasaki K
, et al.
Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial.
Lancet Haematol. 2020;7(7):e523-e533.
PubMed
Google Scholar
D
Ravandi F
,
Jorgensen JL
,
Thomas DA
,
O'Brien S
,
Garris R
,
Faderl S
,
Huang X
,
Wen S
,
Burger JA
,
Ferrajoli A
, et al.
Detection of MRD may predict the outcome of patients with Philadelphia-chromosome positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.
Blood. 2013.
PubMed
Google Scholar
C
Carter BZ
,
Mak PYee
,
Tao W
,
Ayoub E
,
Ostermann LB
,
Huang X
,
Loghavi S
,
Boettcher S
,
Nishida Y
,
Ruvolo V
, et al.
Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics.
Blood Cancer J. 2023;13(1):57.
PubMed
Google Scholar
Jabbour E
,
Sasaki K
,
Ravandi F
,
Huang X
,
Short NJ
,
Khouri M
,
Kebriaei P
,
Burger J
,
Khoury J
,
Jorgensen J
, et al.
Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
Cancer. 2018.
PubMed
Google Scholar